Terumo Europe and University Medical Center Utrecht (UMC Utrecht) recently announced that they have signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. Previously, both parties had successfully collaborated in technology transfers, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Trans-arterial radioembolization, TARE) for the treatment of unresectable liver tumors. The MoU marks the continuation of the existing partnership and confirms the shared interests of both parties to enhance education and innovations to develop meaningful solutions that provide significant clinical benefits to patients with cancer and increase their access to treatments.

Quirem Medical is a wholly owned subsidiary of Terumo (since July 2020), based in Deventer, originated as a spin-off from the UMC Utrecht in 2013. Quirem Medical manufactures QuiremSpheres™, the only commercially available microspheres containing the radioactive isotope Holmium-166. Trials have shown the safety and efficacy of holmium microspheres in the treatment of unresectable liver tumors. Quirem Medical also manufactures the SIRT work-up product QuiremScout™ Holmium-166 Microspheres, which is used prior to the therapy to select patients and plan the SIRT procedure. Across Europe, hundreds of patients are treated with QuiremSpheres™ Holmium-166 microspheres and QuiremScout™ Holmium-166 microspheres every year.

To read more please visit:

https://www.terumo.com/pressrelease/detail/20210719/624/index.html

Source: TERUMO GLOBER WEBSITE